HAP Trading’s Heron Therapeutics HRTX Stock Holding History

HAP Trading’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-39,115	Closed	-$643K	–	1791
2020 Q1	$459K	Buy	+39,115	New	+$735K	0.03%	358
2019 Q4	–	Sell	-13,762	Closed	-$255K	–	1338
2019 Q3	$255K	Sell	13,762 -6,800	-33%	-$125K	0.02%	444
2019 Q2	$382K	Buy	+20,562	New	+$411K	0.03%	388
2018 Q4	–	Sell	-37,757	Closed	-$1.04M	–	1201
2018 Q3	$1.2M	Buy	37,757 +20,517	+119%	+$764K	0.08%	189
2018 Q2	$670K	Buy	+17,240	New	+$549K	0.03%	292
2017 Q1	–	Sell	-154,035	Closed	-$2.02M	–	1154
2016 Q4	$2.02M	Buy	+154,035	New	+$2.42M	0.1%	161
2016 Q1	–	Sell	-120,616	Closed	-$2.38M	–	903
2015 Q4	$3.22M	Buy	+120,616	New	+$3.23M	0.16%	133
2015 Q3	–	Sell	-20,780	Closed	-$693K	–	1104
2015 Q2	$648K	Sell	20,780 -130,817	-86%	-$2.46M	0.04%	318
2015 Q1	$2.21M	Buy	+151,597	New	+$1.71M	0.15%	146

Other funds holding HRTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

HAP Trading's HRTX Position: Q2 2020 in Review

HAP Trading sold out of Heron Therapeutics (HRTX) in Q2 2020, closing a stake of 39,115 shares — an estimated $643K sold.

HAP Trading first reported a position in HRTX in Q1 2015 and held it in 9 quarters. The position peaked at $3.22M in Q4 2015. 190 funds tracked by Wall St. Rank hold HRTX as of Q2 2020.

HAP Trading reported no remaining Heron Therapeutics position as of Q2 2020 after selling out during the quarter.
HAP Trading sold 39,115 Heron Therapeutics shares in Q2 2020, an estimated $643K.
HAP Trading first reported a position in Heron Therapeutics in Q1 2015 and held it in 9 quarters.
HAP Trading's Heron Therapeutics position peaked at $3.22M in Q4 2015.
190 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2020.

Based on HAP Trading's 13F filing for Q2 2020, filed 10 Aug 2020.